The Italian National Health Service is founded on universal coverage and equal access to care.1 In this context, ...
Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. The US Court of Appeals for the Federal Circuit (CAFC) has ...
Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the company. The litigation revolves ...
American entrepreneur and investor Mark Cuban tells us why he and his partners launched the Mark Cuban Cost Plus Drug Company (MCCPDC), a public-benefit corporation and online pharmacy that provides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback